Rosuvastatin is more effective than pravastatin or simavastatin at improving the lipid profiles of hypercholesterolaemic patients

Paoletti, Rodolfo; Fahmy, Maurice; Mahla, Gerhard; Caplan, Richard; Raza, Ali

doi:10.1016/s1567-5688(01)80214-2

Cited by 4 publications

(7 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the reductions in TC, TG and ApoB concentrations observed in this trial are consistent with the effect of rosuvastatin on LDL‐C, the small reductions in HDL‐C and ApoA‐I concentrations are less readily explainable. Data from dose‐ranging [14] and Phase‐III [15–18] trials show that rosuvastatin (1–80 mg) consistently raises HDL‐C in dyslipidaemic patients. It is likely that the atypical decrease in HDL‐C seen in this trial is the result of the relatively short treatment period (2 weeks) and the fact that volun‐teers were required to have baseline LDL‐C concentrations < 4.14 mmol l −1 and baseline TG concentrations ≤ 3.39 mmol l −1 .…”

Section: Discussionmentioning

confidence: 99%

“…Rosuvastatin (Crestor ® ) is a new and highly effective inhibitor of HMG‐CoA reductase that has completed Phase‐III clinical development for the treatment of patients with dyslipidaemia. In clinical trials, rosuvastatin (1–80 mg) produced reductions in LDL‐C, total cholesterol (TC), and triglycerides (TG), and increases in high‐density lipoprotein cholesterol (HDL‐C) [14–18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

Martín

Mitchell

Schneck

2002

Brit J Clinical Pharma

134

101

View full text Add to dashboard Cite

Aims To compare the lipid-regulating effects and steady-state pharmacokinetics of rosuvastatin, a new synthetic hydroxy methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, following repeated morning and evening administration in volunteers with fasting serum low-density lipoprotein cholesterol (LDL-C) concentrations < 4.14 mmol l -1 . Methods In this open-label two-way crossover trial 24 healthy adult volunteers were randomized to receive rosuvastatin 10 mg orally each morning (07.00 h) or evening (18.00 h) for 14 days. After a 4 week washout period, volunteers received the alternative regimen for 14 days. Rosuvastatin was administered in the absence of food. Results Reductions from baseline in serum concentrations of LDL-C ( -41.3%[morning] vs -44.2% [evening]), total cholesterol ( -30.9% vs -31.8%), triglycerides ( -17.1% vs -22.7%), and apolipoprotein B ( -32.4% vs -35.3%) were similar following morning and evening administration. AUC(0,24 h) for plasma mevalonic acid (MVA), an in vivo marker of HMG-CoA reductase activity, decreased by -29.9% (morning) vs -32.6% (evening). Urinary excretion of MVA declined by -33.6% (morning) vs -29.2% (evening). The steady-state pharmacokinetics of rosuvastatin were very similar following the morning and evening dosing regimens. The C max values were 4.58 vs 4.54 ng ml -1 , and AUC(0,24 h) values were 40.1 vs 42.7 ng ml -1 h, following morning and evening administration, respectively. There were no serious adverse events during the trial, and rosuvastatin was well tolerated after morning and evening administration. Conclusions The pharmacodynamic effects and pharmacokinetics of rosuvastatin are not dependent on time of dosing. Morning or evening administration is equally effective in lowering LDL-C .

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

Martín

Mitchell

Schneck

2002

Brit J Clinical Pharma

134

101

View full text Add to dashboard Cite

show abstract

“…This is a prospective cohort study intended to observe the prescribing patterns and doses of anti-hyperlipidemias (Atorvastatin, Rosuvastatin, and Simvastatin) also, assess adherence using the Morisky score [17]. The physician's and patient compliance in prescribing statins according to the guidelines directed medical therapy was assessed and evaluated [18].…”

Section: P E R C E N T a G E O F D R U G L I P I D L O W E R I N G D R U G D I S T R I B U T I O Nmentioning

confidence: 99%

Effect of Multidisciplinary Dyslipidemia Educational Program on Adherence to Guidelines Directed Medical Therapy in Saudi Arabia

AlAyoubi¹,

Hayajneh²,

Alayoubi³

et al. 2021

Int j pharm res allied sci

View full text Add to dashboard Cite

A prospective cohort study was conducted. The practice in three clinics, cardiology, primary care, and endocrine, was assessed by data collection including demographic information, lipid profile (HDL, triglyceride, LDL, total cholesterol), and lipid-lowering drugs. All consecutive patients with hyperlipidemia were included. Extensive educational sessions have been implemented at the beginning of the study. Morisky score was assessed at the initial visit and months 3 and 9 to assess the medication adherence. 401 patients were included with a mean age of 60±13 years, 62 % were males. Evaluation of the prescription pattern of lipid-lowering drugs in outpatient pharmacy revealed 40 % of the hyperlipidemic patients were prescribed lipid-lowering drugs with only 15% was on proper dosing. Rosuvastatin was prescribed more in PCC (60%) while Atorvastatin was more in Cardiology (80%). Initially, the research team conducted a workshop with a campaign to educate the health care practitioners with the guidelines directed to medical therapy. Morisky score calculation was carried out at the beginning, and months 3 and 9. Morisky score was used to evaluate therapy adherence together with knowledge and motivation level. Morisky score initially was above 2 (low adherence) in 43% of the patients and 2 or less (moderate to high adherence) in 57%. Morisky score (above 2) was decreased to 29% from at the first visit (month 3) to 12 % in the last visit (month 9), which reflect on the effectiveness of the extensive education program which was given by the research teams at the beginning of the study.

show abstract

“…In addition, current statins may modestly increase HDL-C levels, by 6–12% [10]. Newer agents in this class that are currently in development include rosuvastatin and pitavastatin [11, 12, 13]. …”

Section: Advances In Statin Therapymentioning

confidence: 99%

“…In a study of patients with primary hypercholesterolaemia, 72% of the patients receiving rosuvastatin (10 mg/day) attained an LDL-C level of <3.0 mmol/l, compared with 52% of patients receiving the same dose of atorvastatin [11]. In a similar study comparing rosuvastatin with simvastatin and pravastatin, 83% of the patients receiving rosuvastatin (10 mg/day) attained an LDL-C level of <3.0 mmol/l, compared with 20% of patients receiving pravastatin (20 mg/day) and 50% of patients receiving simvastatin (20 mg/day) [12]. …”

Section: Advances In Statin Therapymentioning

confidence: 99%

New Advances in Lipid-Modifying Therapies for Reducing Cardiovascular Risk

Bruckert¹

2002

Cardiology

View full text Add to dashboard Cite

Over the last 30 years, several epidemiological and prospective studies have identified a number of risk factors for the development of cardiovascular disease. Lipid abnormalities are central among these risk factors, and their correction has been a major target for the medical community. The 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG-CoA reductase) inhibitors (statins) are the most widely prescribed and best tolerated of the currently available lipid-modifying therapies. Newer agents in this class (e.g. rosuvastatin) have been developed that have proven to be more effective at lowering levels of low-density lipoprotein cholesterol (LDL-C). New formulations of drugs such as nicotinic acid can improve treatment regimens and reduce unpleasant side-effects, thereby improving patient compliance with this therapy. In terms of developing novel drugs, the introduction of cholesterol absorption inhibitors (e.g. ezetimibe) and ACAT inhibitors (e.g. avasimibe) will provide clinicians with therapies that exploit different therapeutic pathways to those currently being utilised. Combining these agents with statins could produce greater improvements in lipid profile than those seen to date. In addition, advances in our understanding of the pathophysiology of dyslipidaemia have led to the identification of other novel therapeutic targets, including cholesteryl ester transfer protein. Studies with experimental drugs have already demonstrated the potential of these approaches.

show abstract

Rosuvastatin is more effective than pravastatin or simavastatin at improving the lipid profiles of hypercholesterolaemic patients

Cited by 4 publications

References 1 publication

Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

Effect of Multidisciplinary Dyslipidemia Educational Program on Adherence to Guidelines Directed Medical Therapy in Saudi Arabia

New Advances in Lipid-Modifying Therapies for Reducing Cardiovascular Risk

Contact Info

Product

Resources

About